Abstract
Oculogyric crisis (OGC) is an acute dystonia which can occur after initiation of antipsychotic treatment. Stereotypic paroxysmal psychiatric symptoms have been described along with OGC that resolve spontaneously when the later remits. We report a case of tardive OGC associated with zuclopenthixol in which there were associated paroxysmal auditory pseudohallucinations.
Keywords: Oculogyric crisis, dystonia, tardive, stereotypic paroxysmal psychiatric symptoms, pseudohallucinations, zuclopenthixol, antipsychotics, ocular pain, agitation, malaise, restlessness, anxiety, schizoid, cognitive, dopaminergic, cholinergic, GABA-ergic, neurobiology, FSC
Current Drug Safety
Title: Stereotyped Paroxysmal Psychiatric Symptoms During Oculogyric Crisis or ‘Cognitive Dystonia’: A Case Report
Volume: 6 Issue: 1
Author(s): Samir Kumar Praharaj, Sujit Sarkhel and Sayeed Akhtar
Affiliation:
Keywords: Oculogyric crisis, dystonia, tardive, stereotypic paroxysmal psychiatric symptoms, pseudohallucinations, zuclopenthixol, antipsychotics, ocular pain, agitation, malaise, restlessness, anxiety, schizoid, cognitive, dopaminergic, cholinergic, GABA-ergic, neurobiology, FSC
Abstract: Oculogyric crisis (OGC) is an acute dystonia which can occur after initiation of antipsychotic treatment. Stereotypic paroxysmal psychiatric symptoms have been described along with OGC that resolve spontaneously when the later remits. We report a case of tardive OGC associated with zuclopenthixol in which there were associated paroxysmal auditory pseudohallucinations.
Export Options
About this article
Cite this article as:
Kumar Praharaj Samir, Sarkhel Sujit and Akhtar Sayeed, Stereotyped Paroxysmal Psychiatric Symptoms During Oculogyric Crisis or ‘Cognitive Dystonia’: A Case Report, Current Drug Safety 2011; 6 (1) . https://dx.doi.org/10.2174/157488611794479982
DOI https://dx.doi.org/10.2174/157488611794479982 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Therapeutic Strategy for Mood Disorders
Current Medicinal Chemistry Chemokines and Autoimmune Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Potent Neuroprotective Activity of Monoterpene Derived 4-[(3aR,7aS)- 1,3,3a,4,5,7a-Hexahydro-3,3,6-trimethylisobenzofuran-1-yl]-2-methoxyphenol in MPTP Mice Model
Letters in Drug Design & Discovery Exploring the Selectivity Profile of Sigma Receptor Ligands by Molecular Docking and Pharmacophore Analyses
Medicinal Chemistry Increased Prevalence of Vestibular Loss in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
Current Alzheimer Research Interplay between Catalysts and Substrates for Activity of Class Ib Aminoacyl-tRNA Synthetases and Implications for Pharmacology
Current Topics in Medicinal Chemistry Resilience to Alzheimer's Disease: The Role of Physical Activity
Current Alzheimer Research Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration
Current Topics in Medicinal Chemistry Clinical Aspects and Therapeutic Perspectives of Relaxin
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Chondroitin Sulphate for the Treatment of Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Polyphenols and Stem Cells for Neuroregeneration in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Impact of Dysfunctional Protein Catabolism on Macrophage Cholesterol Handling
Current Medicinal Chemistry Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy